CDA and pancreatic neoplasm: In two studies, a higher response to treatment with gemcitabine in pancreatic cancer patients was correlated with low circulating CDA activity [26, 27], however, the results were not the same in a later multicenter prospective trial in which 120 patients received treatment with gemcitabine [28].